Clinical Trial Detail

NCT ID NCT03120676
Title Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements no
Sponsors Memorial Sloan Kettering Cancer Center
Indications

Hodgkin's lymphoma

Therapies

Atezolizumab

Age Groups: adult senior

No variant requirements are available.